Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.

Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, Pryer NK.

Clin Exp Metastasis. 2003;20(8):757-66.

PMID:
14713109
2.

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM.

Clin Cancer Res. 2003 Jan;9(1):327-37.

3.

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM.

Blood. 2003 May 1;101(9):3597-605. Epub 2003 Jan 16.

4.

The effect of percutaneous oestradiol on atheroma formation in ovariectomized cholesterol-fed rabbits.

Haines CJ, James AE, Panesar NS, Ngai TJ, Sahota DS, Jones RL, Chang AM.

Atherosclerosis. 1999 Apr;143(2):369-75.

PMID:
10217366

Supplemental Content

Support Center